- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03298334
Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.
Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cesarean section (CS) delivery is a common surgical procedure intended to increase the chances of successful delivery and to protect the health of the mother and baby. Yet this intervention is overused and has been associated with higher risk of immune and metabolic disorders in the offspring. It is hypothesized that these associations are due to CS-delivered newborns not receiving the full inoculum of maternal microbes at birth.
While restoring labor is not possible, restoring the microbes that colonize infants during birth through exposure to vaginal flora, is feasible, and has been shown in a small pilot study, to normalize the microbiota of the intestine, skin and mouth during the first month of life.
The investigators hypothesize that the restoration of the vaginal microbiota to the infant at birth will restore the infant microbiome and decrease the risk of obesity and other immune-mediated diseases linked with CS. The investigators aim to test this hypothesis in a randomized controlled trial by first examining the effect of vaginal seeding, in CS-delivered newborns, on the gut microbiota composition, structure and function (Phase I of study; first 50 infants) and then on the BMI z score and other immune-mediated outcomes (Phase II of study; 600 infants).
Methods: CS-delivered neonates will be randomized to either an experimental arm with exposure to the maternal vaginal microbiota at birth, or a control arm with no exposure. Feces, skin, saliva, breast milk, and vaginal swabs will be collected for microbiome analysis. The investigators will obtain clinical information from in-person visits, surveys and the electronic health record.
Implications: this randomized controlled clinical study will provide evidence of whether the "vaginal seeding" procedure can safely transfer microbes from mom-to-baby, and whether these microbes are beneficial for the metabolic and immune health of the child.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Suchitra Hourigan, MD
- Phone Number: 703-776-8489
- Email: suchitra.hourigan@inova.org, suchitra.hourigan@nih.gov
Study Contact Backup
- Name: Shira Levy
- Phone Number: 703-776-8489
- Email: shira.levy@inova.org
Study Locations
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Recruiting
- Inova Health System
-
Contact:
- Suchitra Hourigan, MD
- Phone Number: 703-776-8489
- Email: suchitra.hourigan@inova.org, suchitra.hourigan@nih.gov
-
Contact:
- General Information
- Email: microbiome@inova.org
-
Sub-Investigator:
- Ankit Shah, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Mother:
- Scheduled for cesarean delivery at ≥ 37 weeks
- Pregnant with single fetus, in good general health, age 18 years or older
- Negative maternal testing for infections transmitted through vaginal and/or other body fluids performed as standard of care tests in early pregnancy
- Negative testing for Group B strep at 35-37 weeks gestation
- Vaginal pH ≤ 4.5 indicative of Lactobacillus-dominated vaginal microbiota
- No maternal or fetal complications that may inhibit the ability to perform microbiome restoration per protocol
- English or Spanish speaking
- Negative maternal testing for Gonorrhea, Chlamydia, Hepatitis B, Hepatitis C, Syphilis, and HIV at 35 weeks gestation or later
- Women aged 18-29 years must have a normal Pap test within 3 years
- Women aged 30-65 years must have a normal Pap test and an HPV test (co-testing) within 5 years or FDA-approved primary hrHPV testing alone within 5 years or a normal Pap test alone within 3 years
- Negative maternal testing for SARS-CoV-2 for the delivery admission performed as standard of care test at the Inova Health System.
Inclusion Criteria for Infant:
- Infant condition after delivery requires no more than standard neonatal resuscitation* or is otherwise medically unable to receive the full VMT procedure
[*] Standard neonatal resuscitation may include: tactile stimulation, bulb suction, oxygen without positive pressure, or drying
Exclusion Criteria for Mother:
- Delivery at a hospital other than Inova Health System
- Cesarean delivery scheduled for active infection that would have interfered with vaginal delivery such as genital herpetic lesions
- Rupture of membranes prior to scheduled cesarean delivery
- Bacterial vaginosis within 30 days of cesarean delivery
- Symptomatic urinary tract infection within 30 days of cesarean delivery
- Antibiotic therapy within 30 days of cesarean delivery (exclusive of medication use for prophylaxis at the time of surgery)
- Symptoms on admission suggesting Chorioamnionitis, e.g. maternal fever, fundal tenderness
- Symptoms on delivery admission of possible vaginal infection such as genital herpetic lesions
- History of genital HSV
- History positive testing for Group B strep infection
- History of a child with a diagnosis of Group B strep sepsis
- Pregnancy a result of donor egg or surrogacy
- Preexisting history of Type I or Type II Diabetes
- Maternal history of documented genital HPV infection, positive HPV testing or genital warts on physician examination
- Positive maternal testing for SARS-CoV-2 within 30 days of delivery or symptoms on admission suggesting potential Covid-19 infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Receives Vaginal Seeding
|
A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
|
Sham Comparator: No Vaginal Seeding
|
A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adiposity
Time Frame: 2 years
|
E.g. Body mass index z-score
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 3 years
|
Monitoring for adverse events
|
3 years
|
Intestinal microbiota
Time Frame: 3 years
|
Intestinal microbiota development over the first three years of life
|
3 years
|
Immune and inflammatory regulation
Time Frame: 3 years
|
E.g.
Monitoring for immune and inflammatory mediated conditions
|
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lawrence Appel, MD, MPH, Johns Hopkins University
- Principal Investigator: Suchitra Hourigan, MD, Chief, Clinical Microbiome Unit, NIAID, Pediatric Gastroenterologist, National Institute of Allergy and Infectious Diseases (NIAID), Inova Children's Hospital
- Principal Investigator: Noel Mueller, PhD, Johns Hopkins University
- Principal Investigator: Maria Gloria Dominguez Bello, PhD, Rutgers University
Publications and helpful links
General Publications
- Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, Cox LM, Amir A, Gonzalez A, Bokulich NA, Song SJ, Hoashi M, Rivera-Vinas JI, Mendez K, Knight R, Clemente JC. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med. 2016 Mar;22(3):250-3. doi: 10.1038/nm.4039. Epub 2016 Feb 1.
- Hourigan SK, Dominguez-Bello MG, Mueller NT. Can maternal-child microbial seeding interventions improve the health of infants delivered by Cesarean section? Cell Host Microbe. 2022 May 11;30(5):607-611. doi: 10.1016/j.chom.2022.02.014.
- Song SJ, Wang J, Martino C, Jiang L, Thompson WK, Shenhav L, McDonald D, Marotz C, Harris PR, Hernandez CD, Henderson N, Ackley E, Nardella D, Gillihan C, Montacuti V, Schweizer W, Jay M, Combellick J, Sun H, Garcia-Mantrana I, Gil Raga F, Collado MC, Rivera-Vinas JI, Campos-Rivera M, Ruiz-Calderon JF, Knight R, Dominguez-Bello MG. Naturalization of the microbiota developmental trajectory of Cesarean-born neonates after vaginal seeding. Med. 2021 Aug 13;2(8):951-964.e5. doi: 10.1016/j.medj.2021.05.003. Epub 2021 Jun 17.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-2694
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Childhood
-
Universiteit LeidenWageningen University; Nutricia, Inc.; Danone ResearchCompletedChildhood Obesity | Childhood Overweight | Vegetable Acceptance in Early ChildhoodNetherlands
-
Vanderbilt University Medical CenterActive, not recruitingPediatric Obesity | Childhood Obesity | Childhood Onset ObesityUnited States
-
Tehran University of Medical SciencesUnknownChildhood Obesity PreventionIran, Islamic Republic of
-
Oregon State UniversityCompletedChildhood Obesity Prevention
-
The Miriam HospitalHassenfeld Child Health Innovation InstituteCompletedChildhood Obesity PreventionUnited States
-
Fundacion para la Formacion e Investigacion Sanitarias...UnknownChildhood Obesity PreventionSpain
-
Tampere UniversitySeinajoki Central Hospital; Tampere University Hospital; Foundation for Paediatric... and other collaboratorsCompleted
-
Cornell UniversityCompletedChildhood Obesity Prevention
-
Harokopio UniversityCompletedPrevention of Childhood ObesityGreece
-
University of Alabama at BirminghamCompletedObesity, Childhood | Overweight, ChildhoodUnited States
Clinical Trials on Vaginal Seeding
-
Peking UniversityNational Natural Science Foundation of China; Liuyang Maternal and Child Health...Active, not recruitingAllergy | Overweight and ObesityChina
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCesarean Section | Microbiome | Vaginal Seeding | NoseUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)RecruitingAsthma | Allergic DiseasesUnited States
-
Walter Reed National Military Medical CenterUnknown
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedVaginal StrictureUnited States
-
University of Wisconsin, MadisonTerminatedSexual Dysfunction, PhysiologicalUnited States
-
University Hospital, BordeauxCompletedMatrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix (MMP-HPV)Papillomavirus Infections | Cervix Cancer | Dysplasia
-
Cairo UniversityCompletedFirst Trimester AbortionEgypt
-
TriHealth Inc.CompletedVaginal Packing Following Pelvic Reconstructive SurgeryUnited States
-
University Hospital, GhentRecruiting